JP2015524055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524055A5 JP2015524055A5 JP2015513339A JP2015513339A JP2015524055A5 JP 2015524055 A5 JP2015524055 A5 JP 2015524055A5 JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015513339 A JP2015513339 A JP 2015513339A JP 2015524055 A5 JP2015524055 A5 JP 2015524055A5
- Authority
- JP
- Japan
- Prior art keywords
- mmp2
- cancer
- levels
- treatment
- angiogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305565.9A EP2667193A1 (en) | 2012-05-23 | 2012-05-23 | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| EP12305565.9 | 2012-05-23 | ||
| PCT/IB2013/054275 WO2013175429A1 (en) | 2012-05-23 | 2013-05-23 | Mmp2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015524055A JP2015524055A (ja) | 2015-08-20 |
| JP2015524055A5 true JP2015524055A5 (https=) | 2016-06-16 |
Family
ID=48782563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513339A Withdrawn JP2015524055A (ja) | 2012-05-23 | 2013-05-23 | ガン患者における抗血管新生療法に対する応答及び該療法後の生存についての予知バイオマーカーとしてのｍｍｐ２ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150148248A1 (https=) |
| EP (2) | EP2667193A1 (https=) |
| JP (1) | JP2015524055A (https=) |
| WO (1) | WO2013175429A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10260097B2 (en) | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
| SG11201504023SA (en) | 2012-12-03 | 2015-06-29 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| KR102652347B1 (ko) * | 2016-01-25 | 2024-03-27 | 사노피 | 혈장 바이오마커 수준의 측정에 의해 암을 앓고 있는 것으로 의심되는 환자의 아플리베르셉트로의 치료 결과를 예측하는 방법 |
| CN107604074B (zh) * | 2017-10-27 | 2020-06-30 | 中南大学湘雅医院 | 胶质瘤预后标志物circ15:101235082|101235577及应用 |
| CN107937532B (zh) * | 2017-12-28 | 2020-06-30 | 中南大学湘雅医院 | 胶质瘤诊断标志物hsa_circ_0021827及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US10260097B2 (en) * | 2011-06-02 | 2019-04-16 | Almac Diagnostics Limited | Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent |
-
2012
- 2012-05-23 EP EP12305565.9A patent/EP2667193A1/en not_active Ceased
-
2013
- 2013-05-23 US US14/402,913 patent/US20150148248A1/en not_active Abandoned
- 2013-05-23 JP JP2015513339A patent/JP2015524055A/ja not_active Withdrawn
- 2013-05-23 EP EP13735437.9A patent/EP2852842A1/en not_active Withdrawn
- 2013-05-23 WO PCT/IB2013/054275 patent/WO2013175429A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bardelli et al. | Liquid biopsies, what we do not know (yet) | |
| Mohankumar et al. | Extracellular vesicle long noncoding RNA as potential biomarkers of liver cancer | |
| Wadhwa et al. | Gastric cancer—molecular and clinical dimensions | |
| Quinn et al. | Extracellular RNAs: development as biomarkers of human disease | |
| Hoseok et al. | Lung cancer biomarkers | |
| Shlyankevich et al. | Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities | |
| Wanhainen et al. | Screening of circulating microRNA biomarkers for prevalence of abdominal aortic aneurysm and aneurysm growth | |
| JP2015524055A5 (https=) | ||
| WO2014140933A3 (en) | Method for the prognosis and treatment of cancer metastasis | |
| Zhang et al. | Increased expression of miR-222 is associated with poor prognosis in bladder cancer | |
| JP2016500110A5 (https=) | ||
| JP2014529405A5 (https=) | ||
| JP2010538609A5 (https=) | ||
| RU2011106957A (ru) | Онкоген nrf2 и его применение | |
| Davey et al. | Evaluating the role of circulating microRNAs to aid therapeutic decision making for neoadjuvant chemotherapy in breast cancer: a prospective, multicenter clinical trial | |
| JP2016536568A5 (https=) | ||
| Wei et al. | Proteome differences between hepatitis B virus genotype-B-and genotype-C-induced hepatocellular carcinoma revealed by iTRAQ-based quantitative proteomics | |
| Ma et al. | Combined overexpression of cadherin 6, cadherin 11 and cluster of differentiation 44 is associated with lymph node metastasis and poor prognosis in oral squamous cell carcinoma | |
| Peng et al. | Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features | |
| Mei et al. | MicroRNAs for diagnosis and treatment of colorectal cancer | |
| Liu et al. | The impact of high co-expression of Sp1 and HIF1α on prognosis of patients with hepatocellular cancer | |
| Liu et al. | Quantitative analysis of HER2 amplification by droplet digital PCR in the follow‐up of gastric cancer patients being treated with trastuzumab after surgery | |
| RU2016135933A (ru) | Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству | |
| Zhang et al. | Higher RABEX-5 mRNA predicts unfavourable survival in patients with colorectal cancer. | |
| Kafle et al. | Current state of knowledge on blood and tissue-based biomarkers for opisthorchis viverrini-induced Cholangiocarcinoma: a review of prognostic, predictive, and diagnostic markers |